Caroline

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9875897/publications.pdf Version: 2024-02-01



CAROLINE

#	Article	IF	CITATIONS
1	Antibody–Drug Conjugates: The Last Decade. Pharmaceuticals, 2020, 13, 245.	3.8	207
2	Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy. European Journal of Medicinal Chemistry, 2017, 142, 393-415.	5.5	64
3	Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors. European Journal of Medicinal Chemistry, 2018, 154, 101-109.	5.5	26
4	Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1. European Journal of Medicinal Chemistry, 2015, 105, 80-105.	5.5	25
5	A small-molecule cell-based screen led to the identification of biphenylimidazoazines with highly potent and broad-spectrum anti-apicomplexan activity. European Journal of Medicinal Chemistry, 2015, 89, 386-400.	5.5	24
6	New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation. Molecules, 2021, 26, 867.	3.8	10
7	In Vitro Characterization and Stability Profiles of Antibody–Fluorophore Conjugates Derived from Interchain Cysteine Cross-Linking or Lysine Bioconjugation. Pharmaceuticals, 2019, 12, 176.	3.8	8
8	Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate. European Journal of Medicinal Chemistry, 2022, 229, 114063.	5.5	7
9	Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells. Pharmaceuticals, 2021, 14, 624.	3.8	6
10	Dibenzofuran Derivatives Inspired from Cercosporamide as Dual Inhibitors of Pim and CLK1 Kinases. Molecules, 2021, 26, 6572.	3.8	3